Press Releases Items Per Page 102550 News Category FinancialGeneral Year None2024202320222021202020192018201720162015201420132012201120102009200820072006 Nektar Publishes Pre-clinical Results for NKTR-214, an Investigational CD122-Biased Immune-Stimulatory Cytokine for the Treatment of Cancer in Clinical Cancer Research Feb 01, 2016 Nektar Therapeutics' President and CEO, Howard W. Robin, To Present at the 34th Annual J.P. Morgan Healthcare Conference in San Francisco, CA Jan 06, 2016 Nektar Therapeutics to Present at Oppenheimer 26th Annual Healthcare Conference in New York Dec 08, 2015 Nektar Announces First Patient Dosed in Phase 1/2 Clinical Study of NKTR-214, a CD122-Biased Immuno-Stimulatory Cytokine Dec 08, 2015 Baxalta Presents Additional Data on Newly-Approved ADYNOVATE and Plans for New Indications During 57th American Society of Hematology (ASH) Annual Meeting Dec 07, 2015 Baxalta Announces U.S. Availability of ADYNOVATE, A New Treatment for Adult Patients with Hemophilia A With a Simple, Twice-Weekly Dosing Schedule Nov 30, 2015 Nektar Therapeutics to Present at Jefferies Autumn 2015 Global Healthcare Conference in London Nov 17, 2015 Baxalta to Advance Care for Hemophilia A patients with FDA Approval of ADYNOVATE, a Simple, Twice-weekly Treatment to Reduce Bleeds Nov 16, 2015 Nektar Therapeutics Reports Financial Results for the Third Quarter of 2015 Nov 05, 2015 Nektar to Announce Financial Results for the Third Quarter 2015 on Thursday, November 5, 2015, After Close of U.S.-Based Financial Markets Oct 29, 2015 Pagination First page « first Previous page ‹ previous … Page 21 Page 22 Page 23 Page 24 Current page 25 Page 26 Page 27 Page 28 Page 29 … Next page next › Last page last »